Abschluss eines nicht exklusiven Rabattvertrages nach§ 130a Abs. 8 SGB V zu Arzneimitteln mit dem Wirkstoff Paliperidon, ausgenommen Depot-Injektionssuspensionen zur Ein-Monats-Dosierung (ATC-Code: N05AX13) innerhalb des Zeitraumes vom 01.11.2026 bis zum 31.10.2028 mit jederzeitiger Möglichkeit des Vertragsabschlusses während der Laufzeit („open-house-Modell“).

TENDER DESCRIPTION

AOK Niedersachsen. The health insurance fund intends, until the entry into force of exclusive agreements following a public tender in accordance with the provisions of Part 4 of the GWB, to enter into non-exclusive pharmaceutical product rebate agreements for the active ingredient Paliperidone, excluding depot injection suspensions for one-month dosing (ATC code: N05AX13), with as many market participants as possible (pharmaceutical entrepreneurs or associations of pharmaceutical entrepreneurs) under the so-called “open-house model”. AOK Niedersachsen will not make a selection decision and will submit an identical contractual offer to each interested pharmaceutical company. Under the open-house model, uniform conditions apply to all participants. Contract content, terms and conditions and access procedures are uniform—individual negotiations are generally not conducted. The agreement terms are a maximum of twenty-four months; the earliest possible contract start date is 01.11.2026. All agreements end no later than 31.10.2028, regardless of the date on which the respective agreement is concluded. An accession and/or the conclusion of an agreement may, within the twenty-four-month…

TENDER BRIEF

TENDER DOCUMENTS